Orphenadrine hydrochloride
Orphenadrine hydrochloride is an orally active and non-competitive NMDA receptor antagonist (crosses the blood-brain barrier) with a Ki of 6.0 μM. Orphenadrine hydrochloride relieves stiffness, pain and discomfort due to muscle strains, sprains or other injuries. Orphenadrine hydrochloride is also used to relieve tremors associated with parkinson's disease. Orphenadrine citrate has good neuroprotective properties, can be used in studies of neurodegenerative diseases.
For research use only. We do not sell to patients.
- CAS No.: 341-69-5
- Formula: C18H24ClNO
- Molecular Weight:305.84
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All iGluR Isoforms
More
Biological Activity
|
NMDA Receptor 6 μM (Ki) |
Orphenadrine hydrochloride (12 μM; 24.5 h) shows neuroprotective effects on 3-NPA-induced neurotoxicity cerebellar granule cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CGC cells (7-day-old Sprague Dawley rat)
-
Concentration:6, 12, 24, 48 µM
-
Incubation Time:24.5 h
-
Result:Prevented cells from 3-NPA induced cellular aggregation,volume diminution and neurite fragmentation.
Orphenadrine hydrochloride (30 mg/kg; i.p.; once aday for 3 days) shows activity to against 3-NPA-induced neuronal damage in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Sprague Dawley rats (275-300 g; 3-NPA toxicity model)[1].
-
Dosage:10, 20, 30 mg/kg
-
Administration:Intraperitoneal injection; once aday for 3 days (30 min before 3-NPA)
-
Result:Reduced mortality of 3-NPA toxicity rats to 10-40% (3-NPA-treated animals showed general incoordination, drowsiness and general weakness).
Recovered 3-NPA-induced body weight loss, and when at 30 mg/kg reduced the level of PBR and expression of HSP27. (PBR and HSP27 are markers of neuronal damage).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 341-69-5
-
Molecular Weight 305.84
-
Formula C18H24ClNO
-
SMILES
CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C.[H]Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Pubill D, et al. Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. Br J Pharmacol. 2001 Feb;132(3):693-702. [Content Brief]
[2]. Kornhuber J, et al. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Orphenadrine hydrochloride Related Classifications
HY-B1126 Related Classifications
Powered by Bioz